Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to $664000.0.

  • Kymera Therapeutics' Change in Accured Expenses fell 7584.58% to $664000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 4079.96%. This contributed to the annual value of $4.2 million for FY2024, which is 3144.65% up from last year.
  • As of Q3 2025, Kymera Therapeutics' Change in Accured Expenses stood at $664000.0, which was down 7584.58% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Change in Accured Expenses peaked at $9.0 million during Q4 2024, and registered a low of -$15.4 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $2.8 million (2022), whereas its average is $958052.6.
  • Per our database at Business Quant, Kymera Therapeutics' Change in Accured Expenses soared by 64274.19% in 2021 and then plummeted by 106936.17% in 2022.
  • Kymera Therapeutics' Change in Accured Expenses (Quarter) stood at $3.8 million in 2021, then dropped by 25.13% to $2.8 million in 2022, then soared by 139.02% to $6.8 million in 2023, then skyrocketed by 32.81% to $9.0 million in 2024, then tumbled by 92.64% to $664000.0 in 2025.
  • Its Change in Accured Expenses was $664000.0 in Q3 2025, compared to $4.8 million in Q2 2025 and -$11.7 million in Q1 2025.